Daré Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Daré Bioscience has a total shareholder equity of $2.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $30.7M and $27.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$23.08m |
| Equity | US$2.86m |
| Total liabilities | US$27.89m |
| Total assets | US$30.75m |
Recent financial health updates
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
Nov 07
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Jul 21Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
Mar 12Recent updates
We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
Nov 07We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Jul 21Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
Mar 12Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Oct 17Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Oct 10Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Aug 29Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Jun 30Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Apr 02Diving Back Into Daré Bioscience Again
Jan 07We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Nov 26Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
Dec 22
Financial Position Analysis
Short Term Liabilities: DARE's short term assets ($25.0M) exceed its short term liabilities ($21.2M).
Long Term Liabilities: DARE's short term assets ($25.0M) exceed its long term liabilities ($6.7M).
Debt to Equity History and Analysis
Debt Level: DARE is debt free.
Reducing Debt: DARE currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DARE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DARE has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 10% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 03:07 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daré Bioscience, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |